Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Diet and Exercise

NCT06411275 is registered in ClinicalTrials.gov with Shenzhen HighTide Biopharmaceutical Ltd. as lead sponsor.

NCT NCT06411275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06411275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Diet and Exercise
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2022
Completion date
January 17, 2023
Enrollment
113 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus